Staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
Shared Decision-Making and Complementary Therapies in Progressive MS
Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.
Early, Aggressive Therapy for Relapsing-Remitting MS
The rationale for initiating aggressive therapy early on to treat patients who present with relapsing-remitting multiple sclerosis.
Differentiating Between the Subtypes of MS
An overview of the clinical subtypes of multiple sclerosis and factors that help neurologists distinguish between each type for an appropriate diagnosis.
Age Considerations: Patients With Nonactive MS Progression
Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.
Monitoring Response in Progressive MS
Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.
Diagnosing MS: Criteria Used to Assess Lesions
Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.
Diagnosing MS: Referring to the Revised McDonald Criteria
Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.
Ibudilast for Progressive Treatment
Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.
Nonactive MS: Treatment Therapies
A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.
Patient Selection in MS Treatment
Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.
Progressive MS Treatment: Ocrelizumab
Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.
MS Treatment: EXPAND Study Versus ASCEND Study
Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.
Siponimod for SPMS Treatment
Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.
Treating PPMS Versus SPMS
A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.
Classification and Diagnosis of SPMS
Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.
Diagnosing SPMS
An overview of the criteria used to diagnose relapsing-remitting multiple sclerosis when it converts to secondary progressive multiple sclerosis.
Clinical Subtypes of MS
A panel of experts led by Bruce Cree, MD, highlight the clinical subtypes of multiple sclerosis including presentation and prevalence.
Robert Fox, MD: The Greatest Need in Progressive Multiple Sclerosis
The neurologist at Cleveland Clinic outlines the need to better understand the biology of progressive MS in order to make substantial headway in its treatment.
Robert Fox, MD: Is Stopping MS Therapy a Reality?
The neurologist at Cleveland Clinic discusses the clinical considerations included in the decision to stop treatment of MS in patients with progressive disease.
Robert Fox, MD: Personalizing Therapies for Patients With Multiple Sclerosis
The staff neurologist at Cleveland Clinic addressed several questions regarding choosing an optimal therapy for patients with MS.
Robert Fox, MD: Targeting Neurodegenerative Processes in Progressive MS
Robert Fox, MD, reviews the current treatment landscape for progressive multiple sclerosis, and why a focus on inflammation may not be sufficient to slow disease progression.
Robert Fox, MD: Exploring New Imaging Biomarkers in Progressive MS
Robert Fox, MD, discussed the pursuit to identify new imaging biomarkers in an effort to better understand the disease course in progressive multiple sclerosis.
Robert Fox, MD: Neurofilament Light and the SPRINT MS Trial
The staff neurologist at Cleveland Clinic shared his insight from the study, as well as what these data can do to further inform the use of this biomarker in progressive MS trials.
Robert Fox, MD: Combining the Symbol Digit Modalities Test and EDSS in Progressive MS
The Cleveland Clinic neurologist explained how the combination of the SDMT and EDSS measurements could improve the phase 3 clinical trial landscape in multiple sclerosis.
Robert J. Fox, MD: Treating Progressive Multiple Sclerosis
The neurologist from Cleveland Clinic discussed the challenges of treating progressive MS, and shared his clinical experience with ibudilast.
Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.